Oseltamivir prophylaxis in controlling influenza outbreak in nursing homes: a comparison between three different approaches

Infection. 2015 Feb;43(1):73-81. doi: 10.1007/s15010-014-0703-4. Epub 2014 Nov 18.

Abstract

Purpose: To assess influenza outbreaks in nursing homes (NHs) using different pharmacological preventive measures.

Methods: We compared characteristics of influenza A outbreaks that occurred during 2011/2012 influenza season in three NHs of similar size (208, 167, and 164 residents in NH1, NH2, and NH3, respectively) implementing comparable treatment approaches and non-pharmacological outbreak control measures but different prophylactic pharmacological interventions including oseltamivir 75 mg o.d. for 10 days for all residents (NH1), for directly exposed residents (NH2), and no prophylaxis (NH3).

Results: The proportions of residents who developed acute respiratory infection (ARI) in the course of influenza outbreak were 55/208 (26.4 %) in NH1, 64/167 (38.3 %) in NH2, and 31/164 (18.9 %) in NH3; hospital admission was required in 2/55 (3.6 %), 5/64 (7.8 %), and 5/31 (16.1 %) residents of NH1, NH2, and NH3, respectively, while 1/55 (1.8 %), 1/64 (1.6 %), and 3/31 (9.7 %) residents of the corresponding NHs died during influenza outbreak. The duration of the outbreak was shorter in the NH1 where oseltamivir prophylaxis was instituted for all residents (8 days), than in NHs where selective prophylaxis with oseltamivir and no prophylaxis were used (14 and 12 days, respectively). The calculated vaccine effectiveness in residents was 48, 71, and 44 % in NH1, NH2, and NH3, respectively. Staff members had similar ARI attack rate but in comparison to residents were less often vaccinated against influenza and demonstrated higher influenza vaccine effectiveness.

Conclusions: Comparison of influenza outbreaks in three NHs revealed that the duration of the outbreak was the shortest in the NH where prophylaxis with oseltamivir was given to all residents.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antibiotic Prophylaxis / methods*
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / therapeutic use*
  • Disease Outbreaks / prevention & control*
  • Female
  • Humans
  • Influenza, Human* / drug therapy
  • Influenza, Human* / epidemiology
  • Influenza, Human* / prevention & control
  • Male
  • Nursing Homes / statistics & numerical data*
  • Oseltamivir / administration & dosage
  • Oseltamivir / therapeutic use*
  • Prospective Studies

Substances

  • Antiviral Agents
  • Oseltamivir